A longitudinal micro-foundational investigation into ambidextrous practices in an international alliance context–A case of a biopharma EMNE

Research output: Contribution to journalArticlepeer-review

Authors

  • Vijay Pereira
  • Swetketu Patnaik
  • Yama Temouri
  • Ashish Malik
  • Oscar Bustinza

Colleges, School and Institutes

External organisations

  • NEOMA Business School
  • Anglia Ruskin University
  • The Petroleum Institute
  • Aston Business School
  • Newcastle Business School
  • Universidad de Granada

Abstract

This paper explores the development of an ambidextrous context in a rapidly growing emerging market multinational (EMNE), thus unbundling cultural and structural complexities. We use the micro-foundational lens of ambidexterity to explore and identify different processes, structures and mechanisms that underpin the development of ambidextrous practices in the EMNE. We adopt a longitudinal case study design to trace the evolution of the EMNE, which during the initial phases of its existence focused on supplying industrial enzymes and refined its technical base. In subsequent years, it exploited its technical base to emerge as a full-fledged biopharmaceutical EMNE and adopted strategic partnerships with international companies to explore new knowledge. Our novel and rich research context also provides us with insights on how this EMNE exploited its technological knowledge, whilst utilizing strategic alliances to simultaneously engage in exploratory activities. Through the micro-foundational lens of ambidexterity, we uncover the critical role played by its leadership in addressing paradoxical tensions for simultaneously managing exploitation and exploration in an international strategic alliance context.

Bibliographic note

Publisher Copyright: © 2020 Elsevier Ltd

Details

Original languageEnglish
Article number101770
Number of pages16
JournalInternational Business Review
Volume30
Issue number1
Early online date28 Nov 2020
Publication statusPublished - Feb 2021

Keywords

  • Ambidexterity, Biopharmaceutical firms, Emerging markets, Micro-foundations, Multinational enterprises, Strategic alliance